Early Detection Research Network

OGG1

Aliases:
This biomarker is also known as:
  • AP Lyase,
  • 8-oxoguanine DNA glycosylase,
  • MUTM,
  • OGG1 Type 1f,
  • OGH1,
  • MMH,
  • HOGG1,
  • OGG1 Type 1h,
  • OGG1 Type 1d,
  • OGG1 Type 1g,
  • OGG1,
  • HMMH,
  • 8-Hydroxyguanine DNA Glycosylase,
  • OGG1 Type 1e,
  • N-Glycosylase/DNA Lyase,
  • DNA-Apurinic Or Apyrimidinic Site Lyase,

Description…

8-Oxoguanine DNA Glycosylase, or OGG1, is a DNA repair enzyme that removes both 7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine (FAPY) from damaged DNA. OGG1 has a beta-lyase activity that nicks DNA 3' to the lesion. There are two major groups of splice variants for this gene, classified by alternative splicing of the C-terminal region of the gene, type 1 and type 2, depending on the last exon of the sequence. Type 1 alternative splice variants end with exon 7 and type 2 end with exon 8. All variants share the N-terminal region in common, which contains a mitochondrial targeting signal that is essential for mitochondrial localization.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Protein
HGNC Name: OGG1

The following organs have data associated with this biomarker…

Attributes

Phase: Two
QA State: Curated

Overview

OGG activity was lower in peripheral blood mononuclear cells from case patients than in those from control subjects. Low OGG activity is associated with an increased risk of lung cancer. Prospective studies are needed to validate these results.

Performance Comment

OGG1 has undergone Phase 2 validation. Work is in progress for Phase 3 validation.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.